Treatment Recommendations for 70-Year-Old Woman with DCIS with Microinvasion
For this 70-year-old postmenopausal woman with 1.8-cm ER-positive DCIS with microinvasion, I recommend breast-conserving surgery with sentinel lymph node biopsy, followed by whole-breast radiotherapy and adjuvant aromatase inhibitor therapy (anastrozole preferred over tamoxifen given her age and lower thromboembolic risk). 1
Surgical Management
Primary Surgery
- Perform breast-conserving surgery (lumpectomy) with adequate margins for this 1.8-cm lesion 1
- Sentinel lymph node biopsy (SLNB) is strongly recommended at the time of definitive surgery, as approximately 25% of patients with seemingly pure DCIS on biopsy will have invasive cancer at final pathology 1
- Recent data shows 12.5% of microinvasive DCIS patients have positive lymph nodes when SLNB is performed 2
- Mastectomy would be considered only if widespread disease (≥2 quadrants) or if margins cannot be achieved with breast conservation 1
Key surgical pitfall: If mastectomy is performed without SLNB and invasive disease is found on final pathology, future SLNB becomes technically impossible, necessitating full axillary dissection 1
Radiation Therapy
Whole-breast radiotherapy should be administered after breast-conserving surgery 1
The evidence strongly supports this:
- RT reduces ipsilateral breast recurrence by 50% (HR 0.49, P<0.00001) 1
- Without RT after BCS, local recurrence rates are significantly higher (6.7% vs 0.9% at 7 years) 1
- For microinvasive DCIS specifically, excellent outcomes are achieved with BCS + RT, with 5-year local-regional-free survival of 98.6% 3
Endocrine Therapy
Aromatase inhibitor (anastrozole) is the preferred endocrine therapy for this postmenopausal patient 1
Why Anastrozole Over Tamoxifen:
The NCCN guidelines specifically recommend aromatase inhibitors for postmenopausal women, especially those under 60 years of age or those with concerns of embolism 1. While this patient is 70, the evidence favors anastrozole:
- NSABP B-35 trial: Anastrozole showed superior breast cancer-free interval compared to tamoxifen (HR 0.73,95% CI 0.56-0.96, P=0.0234) 1
- 10-year breast cancer-free interval: 93.1% with anastrozole vs 89.1% with tamoxifen 1
- Better side effect profile for elderly patients: Lower risk of thromboembolic events (deep vein thrombosis, pulmonary embolism) compared to tamoxifen 1, 4
- Tamoxifen carries higher rates of gynecologic symptoms and thromboembolism, which are particularly concerning in a 70-year-old 1
Endocrine Therapy Strength of Recommendation:
- Category 1 evidence for endocrine therapy after BCS + RT for ER-positive DCIS 1
- Duration: 5 years of therapy 5, 1
Monitoring Considerations:
- Anastrozole increases risk of: arthralgia, myalgia, osteoporosis, hypercholesterolemia 1, 4
- Consider baseline bone density assessment and monitoring
- Monitor lipid profile
- Adherence is critical: women reporting gynecologic symptoms at 6 months are less likely to remain adherent (HR 0.69) 5
Surveillance Protocol
Follow-up schedule 1:
- History and physical examination every 6-12 months for 5 years, then annually
- Annual diagnostic mammography
- First post-treatment mammogram at 6-12 months after completion of RT (category 2B)
Important Caveats
Microinvasion-Specific Considerations:
- Microinvasive DCIS has excellent prognosis with proper treatment: 5-year overall survival 99.4% 3
- Risk factors for worse local control include age <40 and close margins (≤2 mm) 3
- At age 70, this patient has favorable age-related prognosis
No Survival Benefit Caveat:
While endocrine therapy reduces recurrence risk, no survival advantage has been demonstrated for DCIS patients 5, 1, 6. However, reducing ipsilateral and contralateral breast cancer events is itself an important endpoint that improves quality of life by avoiding additional treatments.